NO20054070L - 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. - Google Patents

4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.

Info

Publication number
NO20054070L
NO20054070L NO20054070A NO20054070A NO20054070L NO 20054070 L NO20054070 L NO 20054070L NO 20054070 A NO20054070 A NO 20054070A NO 20054070 A NO20054070 A NO 20054070A NO 20054070 L NO20054070 L NO 20054070L
Authority
NO
Norway
Prior art keywords
quinole
carbonitriles
methoxyphenyl
dichloro
alkoxy
Prior art date
Application number
NO20054070A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054070D0 (no
Inventor
Margaret Maria Zaleska
Diane Harris Boschelli
Frank Charles Boschelli
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054070(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054070D0 publication Critical patent/NO20054070D0/no
Publication of NO20054070L publication Critical patent/NO20054070L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054070A 2003-02-21 2005-09-01 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. NO20054070L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21
PCT/US2004/004904 WO2004075898A1 (en) 2003-02-21 2004-02-19 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (2)

Publication Number Publication Date
NO20054070D0 NO20054070D0 (no) 2005-09-01
NO20054070L true NO20054070L (no) 2005-11-14

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054070A NO20054070L (no) 2003-02-21 2005-09-01 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.

Country Status (19)

Country Link
US (1) US20040229880A1 (es)
EP (1) EP1594502A1 (es)
JP (1) JP2006522023A (es)
KR (1) KR20050102133A (es)
CN (1) CN1750824A (es)
AR (1) AR043253A1 (es)
AU (1) AU2004216235A1 (es)
BR (1) BRPI0407441A (es)
CA (1) CA2516418A1 (es)
CO (1) CO5640114A2 (es)
CR (1) CR7931A (es)
EC (1) ECSP055972A (es)
MX (1) MXPA05008706A (es)
NO (1) NO20054070L (es)
RU (1) RU2005129333A (es)
TW (1) TW200423938A (es)
UA (1) UA80472C2 (es)
WO (1) WO2004075898A1 (es)
ZA (1) ZA200506621B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543163A1 (en) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
SI1802581T1 (sl) * 2004-10-22 2008-08-31 Wyeth Corp 4((2,4-dikloro-5-metoksifenil)amino)-6-alkoksi-7-etinil-3- kinolinkarbonitrili za zdravljenje ishemiäśne poĺ kodbe
WO2007005462A1 (en) * 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
US9120749B2 (en) 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
IN2014CH00840A (es) 2014-02-20 2015-09-18 Apotex Inc
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20060167021A1 (en) * 2002-10-04 2006-07-27 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
AU2004216235A1 (en) 2004-09-10
EP1594502A1 (en) 2005-11-16
MXPA05008706A (es) 2005-10-05
CA2516418A1 (en) 2004-09-10
UA80472C2 (en) 2007-09-25
CO5640114A2 (es) 2006-05-31
KR20050102133A (ko) 2005-10-25
TW200423938A (en) 2004-11-16
WO2004075898A1 (en) 2004-09-10
ECSP055972A (es) 2006-01-16
US20040229880A1 (en) 2004-11-18
JP2006522023A (ja) 2006-09-28
BRPI0407441A (pt) 2006-01-31
RU2005129333A (ru) 2006-01-27
ZA200506621B (en) 2008-02-27
NO20054070D0 (no) 2005-09-01
AR043253A1 (es) 2005-07-20
CN1750824A (zh) 2006-03-22
CR7931A (es) 2006-02-07

Similar Documents

Publication Publication Date Title
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
NO991700L (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
JO2282B1 (en) Oxazole derivatives
WO2008108386A1 (ja) 医薬組成物
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
WO2008114819A1 (ja) 新規アデニン化合物
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
EA200600990A1 (ru) Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
UA66864C2 (uk) Похідні сечовини, фармацевтична композиція і спосіб лікування або профілактики запальних, аутоімунних або респіраторних захворювань
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
DE69529418D1 (de) Cyclopropachromencarbonsäure derivate
ATE501141T1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
WO2006113552A3 (en) Cyanoarylamines
NO20062255L (no) 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
MY145066A (en) Methods for treating sexual dysfunction
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
IL182547A0 (en) 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
CA2441309A1 (en) Biguanide derivatives
TW200745033A (en) Oxindole derivative as feeding control agent
PL353494A1 (en) Novel a-500359 derivatives
TW200612970A (en) Biotinylated hexadecasaccharides, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application